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Abstract
Duchenne muscular Dystrophy (DMD) is an inherited disease caused by mutations in the dystrophin gene that disrupt the
open reading frame, while in frame mutations result in Becker muscular dystrophy (BMD). Ullrich congenital muscular
dystrophy (UCMD) is due to mutations affecting collagen VI genes. Specific muscle miRNAs (dystromirs) are potential non-
invasive biomarkers for monitoring the outcome of therapeutic interventions and disease progression. We quantified miR-1,
miR-133a,b, miR-206 and miR-31 in serum from patients with DMD, BMD, UCMD and healthy controls. MiR-1, miR-133a,b
and miR-206 were upregulated in DMD, but unchanged in UCMD compared to controls. Milder DMD patients had higher
levels of dystromirs than more severely affected patients. Patients with low forced vital capacity (FVC) values, indicating
respiratory muscle weakness, had low levels of serum miR-1 and miR-133b. There was no significant difference in the level of
the dystromirs in BMD compared to controls. We also assessed the effect of dystrophin restoration on the expression of
the five dystromirs in serum of DMD patients treated systemically for 12 weeks with antisense oligomer eteplirsen that
induces skipping of exon 51 in the dystrophin gene. The dystromirs were also analysed in muscle biopsies of DMD patients
included in a single dose intramuscular eteplirsen clinical trial. Our analysis detected a trend towards normalization of these
miRNA between the pre- and post-treatment samples of the systemic trial, which however failed to reach statistical
significance. This could possibly be due to the small number of patients and the short duration of these clinical
trials. Although longer term studies are needed to clarify the relationship between dystrophin restoration following
therapeutic intervention and the level of circulating miRNAs, our results indicate that miR-1 and miR-133 can be considered
as exploratory biomarkers for monitoring the progression of muscle weakness and indirectly the remaining muscle mass in
DMD.
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Introduction
Muscular dystrophies are a group of inherited conditions
characterised by progressive muscle wasting and weakness with
variable severity. The most common muscular dystrophies are
dystrophinopathies, caused by mutations in the dystrophin gene
that depending on the type of mutation, lead to the severe
Duchenne or the milder Becker muscular dystrophy. DMD is an X-
linked disorder and recent figures have refined its incidence to 1 in
5,000 live male births [1,2]. In BMD the clinical course is milder
with a later age of onset and its prevalence is , 1:18,450 [3].
Although there is variability in the severity of the disease in
individual DMD patients, the clinical course follows a well-
described progression. The absence of the dystrophin protein in
DMD leads to disruption of the link between the cytoskeleton and
the extracellular matrix in the muscle fibres and results in muscle
wasting, cycles of muscle fibre regeneration and degeneration,
inflammation and gradual replacement of the muscles by connective
and adipose tissue. This process is reflected clinically in progressive
muscle weakness leading to loss of ambulation by the age of 12
years, and respiratory, cardiac and orthopaedic complications in the
second decade of life, leading to premature death [4].
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The highly heterogeneous group of congenital muscular
dystrophies (CMD) includes a broad range of myopathies,
classified in several groups based on the phenotype and the
affected gene. There is an increasing number of CMD disease
causing genes; among these are collagen VI gene mutations that
cause Ullrich congenital muscular dystrophy and the milder
Bethlem myopathy allelic variant. Both forms are due to either
dominant or recessive mutations in one of COL6A genes (COL6A1,
COL6A2 and COL6A3). In these conditions, the deficiency of
collagen VI at the basal membrane leads to disruption of the link
of the muscle fibres with the extracellular matrix [5]. While in both
DMD and UCMD the primary genetic defect results in myofiber
wasting and replacement by fibro-adipose tissue, the two disorders
have major differences in their pathogenesis and disease manifes-
tations.
Micro RNAs (miRNA) are small RNA sequences (,22
nucleotides) that act as post-transcriptional regulators through
binding to the target mRNA causing repression of the target gene
by inducing mRNA degradation or translational inhibition. Micro
RNAs are conserved in different organisms suggesting a vital role
of these small RNA molecules in regulation of wide range of
biological processes such as development, differentiation, prolifer-
ation and cell death. Aberrant miRNA expression has been shown
in different diseases, e.g. cancer, heart disease, myocardial
infarction and also in muscular dystrophies [6,7,8]. MiR-1, miR-
133a, miR-133b, miR-31 and miR-206 have been referred as
dystromirs in previous studies due to their specific expression in
muscle cells and their role in skeletal muscle maintenance and
regeneration [9]. The expression of miR-1 is initiated by myogenic
regulatory factors and promotes terminal differentiation. Although
miR-1 and miR-133a are expressed from the same transcript, they
have opposite functions in skeletal muscle, with miR-133a
enhancing myoblast proliferation [10]. MiR-206 and miR-133b
are also encoded by a single noncoding RNA expressed only in
skeletal muscles [11]. MiR-206 is expressed in satellite cells,
quiescent muscle precursor cells that contribute to muscle
regeneration [12] and promotes their differentiation and fusion
into multinucleated myotubes [13]. MiR-31 modulates dystrophin
expression by targeting the 3’UTR of dystrophin transcript and
thus repressing the translation of dystrophin mRNA [14]. MiR-31
has been suggested as suitable target in ameliorating strategies for
enhancing dystrophin restoration in exon skipping DMD therapy
[14].
Several studies shed light on the role of microRNAs in the
pathological pathways activated in dystrophic skeletal muscle
[6,9,14,15]. Cacchiarelli and colleagues [9] analysed muscle
specific miRNAs in serum samples from 10 DMD patients and
found increased levels of miR-1, miR-133 and miR-206 in serum
that broadly correlated with the severity of the disease. In a
following study, the same miRNAs were also found increased in
the serum of the canine X-linked muscular dystrophy model
(CXMDJ) over those from age-matched normal dogs [16]. A more
complex picture of the expression of miRNAs was revealed in a
study carried out by Roberts and colleagues who analysed miRNA
expression in different muscles of the mdx mouse, a mouse model of
DMD [17]. A muscle specific pattern of expression was identified
for several miRNAs together with miRNAs showing changes in the
same direction between different muscles (miR-31, miR-1, miR-
133, miR-206). Interestingly, the level of the dystromirs showed a
significant difference between serum and muscle samples. MiR-1,
miR-133a and miR-206 were significantly increased in mdx serum
but downregulated or modestly upregulated in muscle [17].
The studies carried out by Cacchiarelli et al. [9] and Roberts et
al. [17] also showed that the exon skipping therapies aimed at
dystrophin restoration influence the level of circulating dystromirs
in serum of mdx mice. In both studies the elevated levels of miR-1
and miR-206 in the serum of mdx mice were decreased close to the
level in wild type mice following exon skipping therapy and
dystrophin restoration in mdx mice.
No up-to-date studies have investigated serum circulating
miRNAs in UCMD patients and such work is of a particular
interest. The marked fibrosis and reduced regeneration potential is
a feature of UCMD that would probably reflect the miRNAs and
their level in serum.
The present study aims at establishing a baseline of the level of
circulating serum miR-1, miR-133a, miR-133b, miR-206 and
miR-31 in DMD patients, as the previous studies performed
included only a small number of patients. In addition, we aimed to
correlate the amount of the selected serum miRNAs to the disease
severity in DMD patients, assessed using several parameters such
as ambulation status, validated functional assessments (the North
Star Ambulatory Assessment score; (NSAA)), cardiomyopathy,
presence of severe scoliosis requiring surgery and respiratory
forced vital capacity values (FVC). Furthermore, we assessed the
effect that intramuscularly or systemically administered antisense
morpholino oligomer (eteplirsen), which induces targeted skipping
of exon 51 and dystrophin restoration, had on the expression level
of these miRNAs in DMD patients included in two completed
eteplirsen clinical trials [18,19]. Lastly, we have compared the
levels of circulating serum miR-1, miR-133a, miR-133b, miR-206
and miR-31 found in DMD with those detected in UCMD
patients, a muscular dystrophy with completely different patho-
physiology compared to DMD.
Results
Serum levels of miR-1, miR-206, miR-31, miR-133a and
miR-133b in DMD
Upregulation of miR-1, miR-133a and miR-206 in serum has
been previously reported in a small cohort of DMD patients
[9,20]. Here, with the aim to establish a baseline of the level of
serum miR-1, miR-206, miR-31, miR-133a and miR-133b, we
quantified the five dystromirs in a large cohort of DMD patients
(n = 44) and in BMD patients (n = 5). The copy number of the
dystromirs in DMD and BMD was compared to their levels
detected in the serum of 14 healthy controls. T-test for unequal
means was used to examine the differences in the copy number
of the five analysed dystromirs in DMD, BMD patients and
controls. Elevated levels in the serum of DMD patients
compared to the levels in healthy controls were detected for
miR-1 (p = 0.005; 88.7-fold), miR-206 (p,0.0001; 2.35-fold),
miR-133a (p = 0.008; 10.17-fold) and miR-133b (p = 0.0008;
6.9-fold) (Figure 1). MiR-31 showed a higher level in DMD
compared to healthy controls but the result did not remain
significant after multiple comparison correction. MiR-206
showed an increased level in BMD compared to controls
(p,0.05) and different level of miR-133a between DMD and
BMD patients (p,0.05) was detected but they did not remain
significant after multiple testing correction.
miRNAs as serum biomarkers reflecting disease severity
in DMD
Circulating miR-1, miR-133 and miR-206 have been proposed
as potential biomarkers for DMD [9,16,17]. To study whether
miR-1, miR-206, miR-31, miR-133a and miR-133b can serve as
non-invasive biomarkers and aid the monitoring of the disease
progression, we analysed their levels in the serum of 28 ambulant
and 16 non-ambulant DMD patients according to several clinical
Dystromirs as Serum Biomarkers in DMD
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variables: ambulation status, NSAA, cardiomyopathy, scoliosis
severe enough to require surgery, FVC values and steroid regimen
at the time when the serum sample was taken. BMD patients were
not considered in the analysis, as four out of five BMD patients
included in this study were ambulant, without cardiac abnormality
and without severe scoliosis.
A significant difference in the copy number for all of the
dystromirs was detected, with ambulant patients having higher
level of dystromirs compared to non-ambulant patients (Figure
2A). To analyse whether dystromirs quantity in serum could be
utilised as biomarker for physical ability in ambulant DMD
patients, we performed correlation analysis between the NSAA
Figure 1. Serum levels of the analysed dystromirs in DMD, BMD, UCMD and controls. Absolute quantification of miR-1, miR-206, miR-31,
miR-133a and miR-133b in serum samples of 44 DMD, 5 BMD, 16 UCMD patients and 14 healthy controls. The data are presented in a logarithmic
scale as miRNA copy number per ml normalized to the spiked-in C. elegance miRNAs (cel-miR-54, cel-miR-39, cel-miR-238). P-values derived from t-test
are presented with *, **, *** and correspond to p ,0.05, p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0080263.g001
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and the level of the dystromirs in the 26 ambulant DMD patients
(age range between 4 and 13 years) with available NSAA score.
The analysis showed no correlation between the NSAA score and
the amount of dystromirs in serum (Figure 2B).
Scoliosis is a common complication in DMD that often requires
surgical intervention [21]. Analysis of the level of the five studied
dystromirs showed that patients who either had, or were being
considered for, spinal surgery had lower levels of miR-1
(p = 0.0087), miR-31 (p = 0.0025), miR-133a (p = 0.011) and
miR-133b (p = 0.0012) compared to patients who had only mild
or no scoliosis (Figure 3A). The mean age of the patients who
either had, or were considered for, surgery was 15 years and the
mean age of the patients with mild or no scoliosis was 10 years.
However, the difference in the level of miR-1, miR-31, miR-133a
and miR-133b between the two groups was not driven by the age
difference as no significant relationship between miRNA copy
number and age was detected.
Glucocorticoid treatment is the only intervention that can
prolong ambulation, delay respiratory insufficiency and reduce
scoliosis in DMD patients [22]. The two commonly used regimens
are daily and intermittent (10 days on, 10 days off) glucocorticoid
administration. To examine whether there is a difference in the
serum level of the five dystromirs, we compared untreated DMD
patients with those on either an intermittent or daily regimen
(Figure 3B). The analysis showed that patients on the daily, but not
the intermittent, regimen had increased copy number of miR-1
(p = 0.036), miR-31 (p = 0.022) and miR-133b (p = 0.041) com-
pared to untreated patients. MiR-133b also showed higher copy
number in patients on daily compared to patients on intermittent
regimen (p = 0.04). Higher levels of miR-1 (p = 0.025), miR-206
(p = 0.009), miR-133a and miR-133b were detected in patients
who were not on glucocorticoid treatment compared to healthy
controls indicating that the upregulation of miRNAs in the serum
is not due to the glucocorticoid treatment but is a result of the
pathological process in DMD patients (Figure S1), as previously
demonstrated in mdx mice and canine X-linked muscular
dystrophy model (CXMDJ) [16,17,20].
The dystrophin deficiency in DMD patients also leads to
progressive cardiomyopathy with clinically apparent symptoms in
90% of the patients by the age of 18 years [23]. Here, we analysed
the level of miR-1, miR-133a,b, miR-206 and miR-31 in DMD
patients without clinically manifesting cardiomyopathy (n = 31)
and with symptomatic cardiomyopathy (n = 12). None of the
analysed dystromirs showed significant differences in their level in
patients without cardiac abnormality compared to DMD patients
with cardiomyopathy (Figure 3C).
Reduced respiratory function secondary to muscle weakness is
present in DMD patients after the first decade of life and
respiratory complications are the main cause of mortality. FVC
value is an index of respiratory function and can be used as
prognostic marker in DMD [24]. Linear regression analysis in all
DMD patients (n = 44) was carried out in order to determine
whether there is a correlation between the FVC values and the
level of dystromirs detected in serum. A positive correlation was
observed for miR-1 (r2 = 0.34; p = 0.0034) and miR-133b
(r2 = 0.34; p = 0.0035), indicating that low level of miR-1 and
miR-133b are associated with low FVC score (Figure 4).
In addition, linear regression analysis between the quantity of
the dystromirs in serum and the age of DMD patients showed a
weak association for miR-133a (p = 0.039) and miR-133b
(p = 0.016) but it did not remain statistically significant after
Bonferroni correction (Figure 5A). Fluctuating levels of both of
these dystromirs were seen, with a slow decrease in patients
between 4 to 10 years, followed by a considerable decrease in the
amount of miR-133a and miR-133b after the age of 11 years.
MiR-1 showed a similar profile; patients between the age of 4 and
10 years had higher levels than patients after the age of 11 years.
Increased levels of miR-31 in patients in the age range 8 to 11
years were detected followed again with lower amounts of miR-31
in older patients (12 to 17 years). Fluctuating levels of miR-206
throughout the analysed age range were detected. Decreasing
levels of the miRNAs with age were also detected in serum of
UCMD patients (Figure 5B), but we did not see a considerable
decrease in the amount of miR-133a, miR-133b and miR-1 in
older patients, in contrast to our findings in DMD patients. The
serum levels of the five dystromirs in healthy controls followed the
opposite trend to that found in DMD and UCMD, with a slight
increase in the amount of dystromirs with age (Figure 5C).
miRNAs as biomarkers for the outcome of therapeutic
interventions
Systemic phosphorodiamidate morpholino oligomer
(Eteplirsen, AVI-4658) treatment trial. To elucidate wheth-
er the exon skipping therapy and the dystrophin restoration
induced by eteplirsen influenced the serum level of the dystromirs,
we quantified miR-1, miR-206, miR-31, miR-133a and miR-133b
in serum samples taken at baseline (pre-treatment samples) and at
week 12 (post-treatment samples) in 12 DMD patients included in
the systemic antisense oligomer eteplirsen phase II clinical trial
[19]. Eteplirsen induced skipping of exon 51 and restoration of
dystrophin protein expression in a dose dependent, but variable,
manner in the patients from cohort 3 to cohort 6 (Table 1). Five of
the DMD patients (cohort 3, 4, 5, 6) showed a low response, with
skipping of exon 51 detected but no detectable increase in
dystrophin protein production in the post-treatment muscle biopsy
(low responders). Four DMD patients (cohort 5, 6) showed
response at RNA level with increase of dystrophin production in
post-treatment muscle (responders) and three DMD patients
(cohort 3, 5, 6) showed response at RNA level and a greater
increase in dystrophin protein production measured with three
methods of quantification (good responders) [19].
An increase in the serum levels of miR-1, miR-206, miR-31,
miR-133a and miR-133b in pre-treatment samples compared to
controls (n = 14) and an increase of miR-1, miR-206, miR-133a
and miR-133b in post-treatment compared to control samples was
detected (Figure 6A). We tested the difference in the miRNA levels
in pre-treatment and post-treatment samples in all of the analysed
patients. We also analysed the correlation between the amount of
the selected dystromirs in serum and the response to eteplirsen.
The difference between the pre- and post-treatment levels of miR-
1, miR-206, miR-31, miR-133a and miR-133b was also tested in
the patients who received lower dose (cohort 3 and 4) and in
patients who received higher dose of eteplirsen (cohort 5 and 6).
Because of the small number of patients included in the trial and
the variable patient response, the data analysis did not reveal a
conclusive correlation between the amount of miRNAs and the
dystrophin levels in patients treated systemically with eteplirsen
(Figure 6B and 6C). Analysis of samples from ongoing longer
duration studies may better address this issue.
Intramuscular phosphorodiamidate morpholino olig-
omer (Eteplirsen, AVI-4658) treatment trial. Next, we
analysed whether the intramuscular administration of eteplirsen
influenced the expression of the selected dystromirs in the DMD
patients included in the intramuscular eteplirsen clinical trial [18].
A dose-dependent exon skipping was observed and the higher dose
of eteplirsen resulted in increased dystrophin expression in treated
EDB muscles. No dystrophin protein was detected in the patients
who received the low dose of eteplirsen.
Dystromirs as Serum Biomarkers in DMD
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MiR-1, miR-206, miR-31, miR-133a and miR-133b were
quantified in untreated and treated muscle biopsy samples taken 3-
4 weeks after the intramuscular administration of eteplirsen in all
seven DMD patients. No difference in the expression of the
dystromirs in the untreated compared to treated samples could be
detected (Figure 7A).
To investigate whether the expression level of the dystromirs
depended on the dose of eteplirsen and the amount of
dystrophin restoration, we compared the untreated and treated
samples in the two patients who received low dose (0.09 mg) and
in the five patients who received high dose (0.9 mg). The
analysed miRNAs did not showed a significant change in their
expression level after treatment with the two different doses of
eteplirsen (Figure 7B).
In addition, we analysed the expression of miR-1, miR-206,
miR-31, miR-133a and miR-133b in muscle biopsies from four
gender-matched controls and compared them to their expression
in the DMD patients. The most differentially expressed miRNA in
muscle samples was miR-1 which was decreased in DMD patients
(untreated and treated muscles) compared to controls (p,0.001)
(Figure 7A). MiR-31 was also found differentially expressed with
mean fold increase of 15 in DMD patients and showed a trend
towards significance (p = 0.057).
Serum levels of miR-1, miR-206, miR-31, miR-133a
and miR-133b in UCMD. MiR-1, miR-206, miR-31, miR-
133a and miR-133b were quantified in serum samples from
patients with UCMD (n = 16) and the identified serum profile was
compared to that detected in DMD patients and controls. In
contrast to DMD patients, where there was an increase of the
levels of miR-1, miR-206, miR133a and miR-133b in serum, none
of the analysed five dystromirs showed any difference in their copy
number in UCMD patients and their amounts were very similar to
the levels found in controls (Figure 1).
Similarly to DMD, the analysis of the change of the levels in
serum of the five miRNAs with age also showed decreasing
amount of the miRNAs in UCMD patients but the profile was
different between the two muscular dystrophies. Whereas in DMD
we saw a considerable drop of the amount of miR-133a, miR-
133b and miR-1 in patients after the age of 11 years, in UCMD
we did not observe a substantial decrease in the level of these
miRNAs in older patients (Figure 5B).
Further analysis of the amount of circulating miR-1, miR-133a,
miR-133b, miR-206 and miR-31 in the serum of UCMD patients
according to their ambulatory status and FVC score did not show
a significant correlation between the level of the dystromirs and
the analysed clinical variables.
Figure 2. Serum levels of the analysed dystromirs and functional ability of DMD patients. A. MiR-1, miR-206, miR-31, miR-133a and miR-
133b in ambulant and non-ambulant DMD patients. B. Correlation analysis between the level of the dystromirs and the NSAA scores. The data are
presented in a logarithmic scale as miRNA copy number per ml normalized to the spiked-in C. elegance miRNAs (cel-miR-54, cel-miR-39, cel-miR-238).
P-values derived from t-test are presented with **, *** and correspond to p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0080263.g002
Figure 3. Serum level of the analysed dystromirs in DMD patients according to clinical variables. Level of miR-1, miR-206, miR-31, miR-
133a and miR-133b in serum samples of DMD patients: A. without the need of scoliosis surgery and with scoliosis surgery performed or
recommended; B. not on glucocorticoid treatment, on intermittent or on daily steroid regimen; C. without cardiomyopathy and with cardiac
abnormality. The data are presented in a logarithmic scale as miRNA copy number per ml normalized to the spiked-in C. elegance miRNAs (cel-miR-54,
cel-miR-39, cel-miR-238). P-values derived from t-test are presented with *, ** and correspond to p ,0.05 and p,0.01 respectively.
doi:10.1371/journal.pone.0080263.g003
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Discussion
We have performed quantification analysis of the muscle
enriched miRNAs miR-1, miR-206, miR-31, miR-133a and
miR-133b in a large cohort of serum samples from DMD, BMD
and UCMD patients and in serum and muscle samples from
DMD patients treated with exon skipping therapy. This study is
the first to assess the application of these miRNAs as biomarkers
for the disease progression in a large number of DMD patients and
the first to investigate the possibility of utilising specific circulating
miRNAs as non-invasive biomarkers for monitoring the outcome
from exon skipping therapy in DMD patients. We also report for
the first time the serum miRNA profile of the selected five
dystromirs in UCMD, a muscular dystrophy with a different
pathogenesis to DMD.
The first study that investigated circulating miRNAs as
biomarkers for DMD found that miR-1, miR-133 and miR-206
were highly enriched in serum of DMD patients. The authors
reported that the level of miRNAs correlated with the
functional ability assessed using NSAA scores and higher levels
of miRNAs corresponded to low ambulant activity [9].
Limitations of this study were the small number of patients
analysed (n = 10) and the inclusion of only young, still
ambulant, patients (,6 years).
Figure 4. Correlation analysis between the level of the analysed dystromirs in DMD and the FVC values. Linear regression analysis
between the levels of miR-1, miR-206, miR-31, miR-133a and miR-133b in serum samples and FVC scores in DMD patients showed correlation
between the level of miR-1 (p = 0.0034, r2 = 0.34) and miR-133b (p = 0.0035, r2 = 0.34) with the FVC scores. The data are presented as miRNA copy
number per ml normalized to the spiked-in C. elegance miRNA s (cel-miR-54, cel-miR-39, cel-miR-238). Regression lines are also presented.
doi:10.1371/journal.pone.0080263.g004
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The analysis that we performed according to the patients’
ambulation status and NSAA scores showed that ambulant
patients have significantly higher amount of circulating miR-1,
miR-206, miR-31, miR-133a and miR-133b compared to non-
ambulant patients. However, the correlation analysis between
NSAA scores and the level of the five dystromirs in the 26
ambulant patients did not show a significant correlation. The
difference between the two studies is possibly due to the number of
patients included in the NSAA correlation analysis. Our analysis is
based on the data from 26 ambulant patients with available NSAA
scores (age range from 4 to 13 years) whereas Cacchiarelli and
colleagues studied 10 DMD patients with age range between 3 to 6
years of age. The larger number of patients and the broader age
range most likely allowed us to establish a more extensive
correlation between the miRNAs levels and the disease progres-
sion.
Contrary to the previous report [9] that increase in miRNA
levels correlates with more severe muscle damage, our data show
that milder DMD patients have higher levels of dystromirs
compared to more severe DMD patients. All miRNAs were
significantly increased in ambulant patients compared to non-
ambulant patients. MiR-1, miR-31, miR-133a and miR-133b
showed significantly higher levels in patients without the need of
scoliosis surgery compared to patients with scoliosis surgery
performed or recommended. Significantly higher levels of miR-
1, miR-31 and miR-133b were also detected in patients on a daily
steroid regimen, which has been shown to prolong ambulation and
slow down the decline in DMD patients [25]. It is relevant to note
that corticosteroid administration has an anabolic effect in DMD
[26], hence it is likely that the higher doses of corticosteroids are
associated with better muscle mass in treated boys and eventually
higher levels of circulating miRNAs.
An important clinical parameter that provides information
about the progression of respiratory muscle weakness is forced vital
capacity value. A FVC ,40-50% of predicted value significantly
increases the risk of sleep disordered breathing and nocturnal
hypoventilation and the need for non-invasive ventilation [27].
Linear regression analysis between the serum level of the five
dystromirs and the FVC values in DMD patients revealed a
significant positive correlation for miR-1 and miR-133b and the
FVC value. Patients with low FVC values, indicating respiratory
muscle weakness, have low levels of miR-1 and miR-133b and
higher serum levels of the two miRNAs correspond to better lung
function. These data further suggest that miR-1 and miR-133b
might serve as non-invasive diagnostic markers for monitoring the
progression of muscle weakness in DMD.
The analysis between the level of the five miRNAs in serum and
the age of the DMD patients provided more information about the
change of the amount of miRNAs over time. MiR-1, miR-133a
and miR-133b showed a similar age pattern: higher and gradually
decreasing level in patients between 4 to 10 years old and
considerably lower levels of miRNAs in older patients (from 13 to
17 years of age). Based on the age profile of miR-1, miR-133a and
miR-133b, we can speculate that the three dystromirs can be
utilised as biomarkers for the remaining muscle mass in DMD. In
the early stages of the disease the changes in the muscle pathology
consist of fibre size variation and pronounced degeneration and
regeneration processes. With the advance of the disease there is
less regeneration activity, progressive loss of muscle fibres and their
replacement by connective and adipose tissue. In the terminal
stage of the disease, the muscles mainly consist of adipose tissue
with residual muscle fibres [28]. We can speculate that in DMD
the gradual loss of muscle fibres leads to gradual decrease of the
amount of miRNAs released from the muscles and consequently a
decrease in the amount of miRNAs in serum. Our data show
higher amounts of miR-1, miR-133a and miR-133b in serum of
DMD patients in the early stage of the disease (age 4 to 10 years)
and decrease of these miRNAs with the progression of the disease
where the low amount of circulating miRNAs might reflects the
loss of muscle fibres and their replacement by connective and
adipose tissue. However, more functional studies showing the
relationship between the quantity of circulating miRNAs and the
residual muscle mass in the dystrophic muscles are necessary.
When the expression of miR-1, miR-31, miR-206, miR-133a
and miR133b was compared in muscle to serum from DMD
patients, a difference in the profile of the dystromirs was seen
which is consistent with previous reports in mdx mice [17,20]. The
greatest difference was found for miR-1, which had decreased
expression in DMD muscle samples but was highly abundant in
serum. The miRNAs that were upregulated in serum (miR-206,
miR-133a and miR-133b) did not show a change in their
expression in the analysed muscle samples. The differences in
the profiles between muscle and serum detected in our data
support the notion that the circulating miRNAs are not simply a
result of ‘‘leaky’’ muscles, where the sarcolemmal damage causes
spontaneous release of miRNAs from the damaged muscle into the
blood. It has been proposed that miRNAs are actively secreted and
released from the muscles as a result of a specific biological
response to the dystrophic conditions [17].
Figure 5. Age profile of miR-1, miR-206, miR-31, miR-133a and miR-133b in serum samples. Level of miR-1, miR-206, miR-31, miR-133a
and miR-133b in serum samples according to the age of the: A. DMD patients; B. UCMD patients; C. healthy controls. The data are presented as
miRNA copy number per ml normalized to the spiked-in C. elegance miRNAs (cel-miR-54, cel-miR-39, cel-miR-238). Regression line is also presented.
doi:10.1371/journal.pone.0080263.g005
Table 1. Deletion, dose escalating scheme and response of
the patients who participated in the systemic eteplirsen
clinical trial.
Patient ID
Response to
eteplirsen Cohort Deletion
P7 +++ Cohort 3 (2 mg/kg) 49–50
P8 + Cohort 3 (2 mg/kg) 49–50
P10 + Cohort 4 (4 mg/kg) 48–50
P11 + Cohort 4 (4 mg/kg) 45–50
P12 ++ Cohort 5 (10 mg/kg) 49–50
P13 ++ Cohort 5 (10 mg/kg) 48–50
P14 + Cohort 5 (10 mg/kg) 47–50
P15 +++ Cohort 5 (10 mg/kg) 49–50
P16 + Cohort 6 (20 mg/kg) 45–50
P17 ++ Cohort 6 (20 mg/kg) 45–50
P18 +++ Cohort 6 (20 mg/kg) 49–50
P19 ++ Cohort 6 (20 mg/kg) 45–50
Response to eteplirsen: + shows response only at RNA level ; ++ shows response
at RNA level and increase of dystrophin expression in post-treatment muscle;
+++ shows response at RNA level and a greater increase in dystrophin
production in post-treatment muscle measured with three methods of
quantification.
doi:10.1371/journal.pone.0080263.t001
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Previous studies carried out in mdx mice showed elevated levels
of circulating dystromirs, which were partly normalised to the wild
type level after exon skipping therapy [9,17]. Our analysis in
DMD patients did not identify a significant difference when the
levels of dystromirs were compared in serum samples before
treatment and in post-treatment samples taken at week 12, when
the last dose of eteplirsen was administered, despite an encour-
aging trend for normalisation of the miRNAs. Further analysis in
the DMD patients according to the dose and response to eteplirsen
did not reveal a conclusive result of the difference in the level of
the studied miRNAs before and after treatment. We also analysed
the same dystromirs in untreated and treated muscle samples in
seven patients who received a single intramuscular infusion of
eteplirsen. Similar to the results in serum samples, no difference in
the expression levels of the dystromirs in untreated and treated
muscle biopsies was detected and we could not detect a dose
dependent change in the expression of the analysed miRNAs in
patients who received either a low or high dose of eteplirsen [18].
The lack of a statistically significant difference between the
untreated and treated samples could be due to a number of
possibilities. One relates to the high variability that we observed in
the levels of the analysed dystromirs in individual patients, which is
in agreement with previous reports in mdx mice [17]. Due to the
variability, a slight change in the levels of the dystromirs after
therapeutic intervention will be difficult to identify when analysing
small cohorts of patient samples, unless the therapeutic effect was
overwhelming. The lack of statistically significant changes in the
expression of miRNAs after exon skipping therapy may also be
due to the small number of patients analysed. For example, only
eight patients received higher dose of eteplirsen in the systemic
clinical trial and a reliable assessment of the relationship between
the outcome from exon skipping therapy and the change in the
expression of dystromirs based on such numbers of patients
represent a challenge. Another important point relates to the short
duration of our study (12 weeks). Assessment of miRNAs in studies
with longer duration, such as the recently reported eteplirsen 48
weeks trial, with doses of phosphorodiamidate morpholino
oligomer up to 50 mg/kg/wk, could be more informative [29].
Indeed, a recent study in mdx mice using a morpholino antisense
oligonucleotide, administered systemically at a dose equivalent to
the one used in DMD clinical trials, showed that long-term
administration increases dystrophin restoration [30]. The authors
showed that the duration of the treatment was critical for the
increase of dystrophin in skeletal muscle with the number of
positive fibres and amount of dystrophin doubling after 50 weeks
of treatment compared to 20 weeks. In our study the five
dystromirs were analysed in serum samples taken after 12 weeks of
eteplirsen treatment. A possible explanation for the lack of
significant difference in the level of miRNAs in pre-treatment
and post-treatment samples in patients recruited in our trial is that,
although 12 weeks of treatment induced restoration of dystrophin
expression in DMD patients [19], the 12-week time point might
not be sufficient to assess response to therapy at the miRNA level,
as the amount of dystrophin is still slowly increasing. The
difference in the level of the circulating dystromirs in DMD
patients with different severity and the higher amount of miRNAs
in the patients with possibly more muscle mass that we detected in
the current study suggest that miRNAs are valuable biomarkers in
DMD. The quantification of miRNAs in serum after a more
prolonged period of time might well be informative in treated boys
and should be investigated in future clinical trials.
In the present study we also quantified miR-1, miR-206, miR-
31, miR-133a and miR-133b in serum samples from Ullrich
Congenital Muscular Dystrophy patients. In contrast to DMD,
where we found an increase of miR-1, miR-206, miR-133a and
miR-133b, none of the analysed dystromirs in UCMD showed
dysregulated levels. In addition, there was a decrease in the
amount of the serum miRNAs with age in UCMD patients,
possibly due to the loss of muscle fibres with the progression of the
disease, but the profile was different from that detected in DMD.
The different pathological mechanism of DMD and UCMD might
explain the differences in the levels of the analysed dystromirs in
serum. In DMD the disrupted muscle membrane leads to gross
leakage and elevated serum levels of creatine kinase (CK), followed
by florid necrosis, regeneration and inflammation, while UCMD
patients have normal or slightly elevated CK levels, and less signs
of regeneration or inflammatory infiltration. This suggests that
pathogenesis of the muscle fibre degeneration in UCMD is
different from DMD [31], as also highlighted by recent data on
mitochondrial damage, which is restricted to UCMD, and
autophagy, more prominent in UCMD [32,33,34]. The dynamics
of muscle regeneration are also very different between DMD and
UCMD. The extracellular matrix in DMD is initially not
disrupted, allowing satellite cell-mediated regeneration, whereas
such regeneration does not occur in UCMD, possibly due to the
effect of the lack of collagen VI on satellite cell function [35].
In a recent study, serum miRNAs were analysed in four mouse
models for muscle pathologies: DMD (mdx), limb-girdle muscular
dystrophy type 2D (sgca-null mice) and type 2C (sgcg-null mice) and
Emery-Dreifuss muscular dystrophy (KI-Lmna) [20]. Upregulation
of miR-1, miR-133a and miR-133b in serum was detected in the
mouse models for DMD, limb-girdle muscular dystrophy type 2D
(LGMD2D) and type 2C (LGMG2C) but the three miRNAs were
slightly downregulated in the model for Emery-Dreifuss muscular
dystrophy (EDMD). The results show that upregulation of miR-1,
miR-133a and miR-133b in serum is not specific to DMD but is
most likely associated with the pathological process occurring in
the muscles. While a more pronounced dystrophic process, with
muscle fibres wasting and cycles of degeneration and regeneration,
is characteristic of DMD, LGMD2D and LGMG2C, in UCMD
and in EDMD the dystrophic pathology is milder with lower level
of regeneration and degeneration [20,36]. Although more research
in needed to show the relationship between the pathological
process in dystrophic muscles and the release of specific miRNAs
in the circulation, we can speculate that due to the different
pathological mechanism in DMD and UCMD, different sets of
miRNAs are expressed in muscle and in blood.
The urgent need for developing non-invasive biomarkers for the
assessment of the muscle pathology in muscular dystrophy patients
is defined by the fact that currently biochemical outcome studies of
clinical trials need for a muscle biopsy, which is limited to a single
time point, single muscle, is invasive and not desirable in children.
Figure 6. miRNAs as biomarkers for the outcome of therapeutic interventions: Systemic eteplirsen treatment trial. Absolute
quantification of miR-1, miR-206, miR-31, miR-133a and miR-133b in serum of: A. DMD patients before treatment with eteplirsen (pre-treatment), after
treatment (post-treatment) and controls; B. low responders, responders and good responders; C. patients who received low dose and patients with
high dose of eteplirsen. The data are presented in a logarithmic scale as miRNA copy number per ml normalized to the spiked-in C. elegance miRNAs
(cel-miR-54, cel-miR-39, cel-miR-238). P-values derived from two-tailed t-test are presented with *, *** and correspond to p ,0.05 and p,0.001
respectively.
doi:10.1371/journal.pone.0080263.g006
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MiRNAs represent an excellent class of blood-based biomarkers
for DMD as they are present in a stable form in serum and
plasma samples and their evaluation in blood-derived products
represents a less invasive method compared to muscle biopsies.
Although it remains difficult to conclude from our study
whether circulating miR-1, miR-206, miR-31, miR-133a and
miR-133b could be utilised as non-invasive biomarkers for
monitoring the outcome from exon skipping therapeutic
interventions, which will require longer studies than the one
we have been involved with, we propose miR-1, miR-133a and
miR-133b as reliable biomarkers for evaluating the disease
progression and possibly monitoring the remaining muscle mass
in DMD.
Materials and Methods
Study participants
DMD, BMD, UCMD and healthy controls serum
cohort. The study was approved by the Berkshire Research
Ethics Committee (REC reference 05/MRE12/32). Serum
samples were supplied by the MRC CNMD Biobank London
(REC reference number 06/Q0406/33) and were collected from
individuals under a written informed consent of parents or legal
guardians. All samples have been supplied to the project
anonymised. Copies of the consent forms are kept with the
Biobank in a locked cabinet and are also available in the patient’s
hospital notes at Great Ormond Street Hospital for Children and
Hammersmith Hospital. Serum samples collection at the CMD
comparative outcome measures study (COM) at the National
Institutes of Health (NIH), Bethesda, MD, USA and Cincinnati
Children’s Hospital Medical Centre (CCHMC), Cincinnati, OH,
USA was approved by Cincinnati Children’s Hospital Medical
Center Investigational Review Board and all serum samples were
collected from individuals under a written informed consent of
parents or legal guardians.
The DMD and BMD patients were recruited for the study from
the clinical population at Great Ormond Street Hospital, London.
Sixteen DMD patients were non-ambulant with mean age of 14
years (age range between 10 and 17 years) and 28 DMD were
ambulant with mean age of 8.2 years (age range 4 to 13 years). All
BMD patients (n = 5) were ambulant with mean age of 13.6 (age
range between 9 and 18 years).
Six serum samples from UCMD patients were collected at
Great Ormond Street Hospital, London and ten samples were
collected at CCHMC and the COM study at the NIH. Nine of the
UCMD patients were non-ambulant (mean age 11.5, age range
5.9–16.8 years) and seven patients were ambulant (mean age 9.3
years, range 6.6–13 years).
Serum samples from fourteen healthy individuals were collected
under a written informed consent: four serum samples were
collected at Great Ormond Street Hospital, London and ten at
Cincinnati Children’s Hospital Medical Centre. The mean age of
the controls was 8.1 years and ranged between 2.9 and 15.9 years.
All serum samples are stored with consent in the MRC Centre
for Neuromuscular Diseases Biobank, London (http://www.cnmd.
ac.uk).
Additional information about the participants is provided in
Table S1.
Muscle biopsy samples from healthy controls. Four
skeletal muscle biopsies from gender-matched controls were
obtained under written informed consent and stored in the
MRC Centre for Neuromuscular Diseases Biobank, London.
Muscle biopsies from DMD patients included in the
intramuscular eteplirsen treatment trial. The expression
profiles of the selected dystromirs were analysed in skeletal muscle
biopsies obtained under written informed consent from families
and assent from patients included in the previously reported
intramuscular eteplirsen treatment study [18] and stored in the
MRC Centre for Neuromuscular Diseases Biobank, London.
Ethical approval was obtained from the UK Gene Therapy
Advisory Committee and local research ethics committees. The 7
patients studied were between 10 and 17 years and had a deletion
that could be rescued by the skipping of exon 51 (Table 2).
Eteplirsen was administrated into one extensor digitorum brevis
muscle (EDB) and the contralateral muscle received an equivalent
volume of normal saline. Bilateral EDB biopsies were obtained 3
to 4 weeks after treatment. The expression of the dystromirs was
analysed in the biopsies from untreated and treated muscles from
the two patients who received a low dose of 0.09mg of eteplirsen
and from the five patients who received a high dose of 0.9mg of
eteplirsen.
Serum samples from DMD patients participated in
the systemic eteplirsen treatment trial. Blood samples from
the DMD patients who took part in a previously completed
systemic clinical trial [19] were collected under written informed
consent from parents and assent from children and stored in the
MRC Centre for Neuromuscular Diseases Biobank, London.
Ethical approval was obtained from the UK Gene Therapy
Advisory Committee and local research ethics committees. The
DMD patients were ambulant, aged 5–15 years with an out-of-
frame deletion eligible for correction by skipping of exon 51 of the
dystrophin gene. Eteplirsen was administrated in 12 weekly
intravenous infusions. We analysed the level of the dystromirs in
serum samples from DMD patients from cohort 3 (2 cases, 2 mg/
kg), cohort 4 (2 cases, 4 mg/kg), cohort 5 (4 cases, 10 mg/kg) and
cohort 6 (4 cases, 20 mg/kg) (Table 1). Analysis of the selected
dystromirs was performed in serum samples obtained from blood
taken .10 days prior to the first dose of study drug (baseline) and
at week 12.
RNA preparation and RT-PCR analysis
Serum samples were prepared from 1.5 ml to 4 ml of blood
taken in BD vacutainer tubes. The blood sample was allowed to
clot at room temperature for 30 minutes, followed by centrifuga-
tion at 2850g for 10 minutes. Serum supernatant was carefully
collected, aliquoted in volumes of 200 ml in eppendorf tubes and
stored at –80uC until use.
Total RNA was extracted from 200 ml serum samples using
miRNeasy kit (QIAGEN) following the manufacturer’s protocol
for liquid samples. For data normalization, we used a pool of
artificial Caenorhabditis elegans miRs (cel-miR-54, cel-miR-39, cel-miR-
238) added as a mixture of 25 fmol each in a 5 ml volume as
previously described [37].
Total RNA from muscle biopsy samples was extracted using
miRNeasy kit (QIAGEN) following the manufacturer’s protocol
for tissue samples.
Figure 7. miRNAs as biomarkers for the outcome of therapeutic interventions: Intramuscular eteplirsen treatment trial. MiR-1, miR-
206, miR-31, miR-133a and miR-133b expression in: A. untreated and treated muscle biopsy samples and controls; B. patients who received low dose
and patients with high dose of eteplirsen. The data are presented in a logarithmic scale as relative fold change with respect to the control samples
and normalized to U6 snRNA expression. P-values derived from two-tailed t-test are presented with *** and correspond to p,0.001.
doi:10.1371/journal.pone.0080263.g007
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qRT-PCR was performed using TaqMan small RNA Assay
(Applied Biosystems) following the manufacturer’s protocol.
Briefly, a fixed volume of 5 ml of total RNA of a given sample
was reverse transcribed using TaqMan MicroRNA Reverse
Transcription kit. The PCR amplification of a volume of 1.33 ml
cDNA was carried out using TaqMan Universal PCR master mix
and miRNA-specific stem-loop primers (Applied BioSystems).
The copy number analysis of the level of miRs in serum was
performed using standard curves prepared for each of the
analysed miRNAs and a median normalization procedure with
a normalization factor calculated using the Ct values obtained
from the artificial spiked-in cel-miRs [37]. For the miRNA
expression analysis in muscle samples we used the DDCt
method and U6 snRNA as endogenous control for data
normalization.
Statistical analysis
Comparisons between paired sample data were performed using
a two-tailed Student’s T test (two sample sets) and ANOVA for
multiple sample data sets. Tests for linear relationships were
carried out using linear regression. A p-value ,0.05 was
considered significant, allowing for multiple comparison correc-
tion, and analyses were carried out using R [38] and GraphPad
(GraphPad Prism version 5 for Windows, GraphPad Software, La
Jolla California USA, www.graphpad.com).
Supporting Information
Figure S1 Serum level of dystromirs in healthy controls and
DMD patients on different glucocorticoid treatment regimen.
Level of miR-1, miR-206, miR-31, miR-133a and miR-133b in
serum samples of healthy controls, DMD patients not on
glucocorticoid treatment, on intermittent and on daily treatment
regimen. The data are presented in a logarithmic scale as miRNA
copy number per ml normalized to the spiked-in C. elegance
miRNAs (cel-miR-54, cel-miR-39, cel-miR-238). P-values derived
from t-test are presented with *, ** and correspond to p,0.05 and
p,0.01 respectively.
(TIF)
Table S1 The study cohort: DMD, BMD, UCMD and healthy
controls. Presented are gender, age, ambulatory status, NSAA
score, scoliosis surgery performed, FVC value and glucocorticoid
regimen. NA: not available/not assessed.
(DOCX)
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